Patompong Ungprasert1, Narat Srivali1, Wonngarm Kittanamongkolchai1. 1. 1 Division of Rheumatology, Department of Internal Medicine, 2 Division of Pulmonary and Critical Care, Department of Medicine, 3 Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
OBJECTIVE: To investigate the association between coronary artery disease (CAD) and ankylosing spondylitis (AS). METHODS: We conducted a systematic review and meta-analysis of observational studies that reported relative risks, hazard ratios, standardized prevalence ratio or standardized incidence ratios with 95% confidence comparing CAD risk in patients with AS versus non-AS controls. Pooled risk ratios and 95% confidence intervals (CIs) were calculated using a random-effect, generic inverse variance of DerSimonian and Laird. RESULTS: Out of 229 potentially relevant articles, ten studies (five retrospective cohort studies and five cross-sectional studies) were identified and included in our data analysis. The overall pooled risk ratio of CAD in patients with AS was 1.41 (95% CI: 1.29-1.54). The pooled risk ratios for cross-sectional and cohort studies were 2.08 (95% CI: 1.28-3.40) and 1.36 (95% CI: 1.31-1.41), respectively. The statistical heterogeneity of this meta-analysis was moderate with an I(2) of 56%. CONCLUSIONS: Our study demonstrated a statistically significant increased CAD risk among patients with AS with 41% excess risk.
OBJECTIVE: To investigate the association between coronary artery disease (CAD) and ankylosing spondylitis (AS). METHODS: We conducted a systematic review and meta-analysis of observational studies that reported relative risks, hazard ratios, standardized prevalence ratio or standardized incidence ratios with 95% confidence comparing CAD risk in patients with AS versus non-AS controls. Pooled risk ratios and 95% confidence intervals (CIs) were calculated using a random-effect, generic inverse variance of DerSimonian and Laird. RESULTS: Out of 229 potentially relevant articles, ten studies (five retrospective cohort studies and five cross-sectional studies) were identified and included in our data analysis. The overall pooled risk ratio of CAD in patients with AS was 1.41 (95% CI: 1.29-1.54). The pooled risk ratios for cross-sectional and cohort studies were 2.08 (95% CI: 1.28-3.40) and 1.36 (95% CI: 1.31-1.41), respectively. The statistical heterogeneity of this meta-analysis was moderate with an I(2) of 56%. CONCLUSIONS: Our study demonstrated a statistically significant increased CAD risk among patients with AS with 41% excess risk.
Authors: Juliet Evans; Julia H Goedecke; Ingegerd Söderström; Jonas Burén; Malin Alvehus; Caroline Blomquist; Fredrik Jonsson; Philip M Hayes; Kevin Adams; Joel A Dave; Naomi S Levitt; Estelle V Lambert; Tommy Olsson Journal: Clin Endocrinol (Oxf) Date: 2011-01 Impact factor: 3.478
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Raúl Herzog; María José Álvarez-Pasquin; Camino Díaz; José Luis Del Barrio; José Manuel Estrada; Ángel Gil Journal: BMC Public Health Date: 2013-02-19 Impact factor: 3.295
Authors: Ho Soo Chun; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim Journal: Dig Dis Sci Date: 2021-09-02 Impact factor: 3.487
Authors: Areej O Bawajeeh; Salwa A Albar; Huifeng Zhang; Michael A Zulyniak; Charlotte E L Evans; Janet E Cade Journal: Nutrients Date: 2020-07-03 Impact factor: 5.717
Authors: Sukki Park; Ji Hyun Lee; Joon Sul Choi; Hyun Woo Kim; Beom Jin Shim; Won Kyu Choi; Sang Hyun Kim Journal: Yeungnam Univ J Med Date: 2018-06-30